{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:16:06Z","timestamp":1790295366497,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40120-025-00856-1","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T12:16:09Z","timestamp":1764591369000},"page":"309-324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Foslevodopa\/Foscarbidopa in Younger Patients Earlier Within Advanced Parkinson\u2019s Disease: Post\u00a0Hoc Analysis of a Randomized Trial"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct04380142","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1040-2807","authenticated-orcid":false,"given":"Angelo","family":"Antonini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-8262","authenticated-orcid":false,"given":"Bruno","family":"Bergmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7317-3787","authenticated-orcid":false,"given":"Drew S.","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2874-9817","authenticated-orcid":false,"given":"Florin","family":"Gandor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7762-3597","authenticated-orcid":false,"given":"Noriko","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2921-8348","authenticated-orcid":false,"given":"David G.","family":"Standaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjoern","family":"Fritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Resmi","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megha B.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kimber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"issue":"1","key":"856_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000215875","volume":"62","author":"RA Hauser","year":"2009","unstructured":"Hauser RA. Levodopa: past, present, and future. Eur Neurol. 2009;62(1):1\u20138.","journal-title":"Eur Neurol"},{"issue":"8","key":"856_CR2","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S1474-4422(06)70521-X","volume":"5","author":"CW Olanow","year":"2006","unstructured":"Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson\u2019s disease: scientific rationale and clinical implications. Lancet Neurol. 2006;5(8):677\u201387.","journal-title":"Lancet Neurol"},{"issue":"2","key":"856_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141\u20139.","journal-title":"Lancet Neurol"},{"issue":"12","key":"856_CR4","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","volume":"21","author":"MJ Soileau","year":"2022","unstructured":"Soileau MJ, Aldred J, Budur K, et al. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson\u2019s disease: a randomised, double-blind, active-controlled, phase\u00a03 trial. Lancet Neurol. 2022;21(12):1099\u2013109.","journal-title":"Lancet Neurol"},{"key":"856_CR5","unstructured":"VYALEV (foscarbidopa and foslevodopa). Prescribing information. AbbVie Inc; 2024. https:\/\/www.rxabbvie.com\/pdf\/vyalev_pi.pdf. Accessed 27 May\u00a02025."},{"issue":"6","key":"856_CR6","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s40120-023-00533-1","volume":"12","author":"J Aldred","year":"2023","unstructured":"Aldred J, Freire-Alvarez E, Amelin AV, et al. Continuous subcutaneous foslevodopa\/foscarbidopa in Parkinson\u2019s disease: safety and efficacy results from a 12-month, single-arm, open-label, phase\u00a03 study. Neurol Ther. 2023;12(6):1937\u201358.","journal-title":"Neurol Ther"},{"key":"856_CR7","unstructured":"de Fabregues O, Falconer D, Heshmat S, et al. Long-term evolution of advanced Parkinson\u2019s disease burden: subgroup analysis from the 24\u00a0month international PROSPECT observational study [abstract]. Mov Disord. 2024;39(suppl 1). https:\/\/www.mdsabstracts.org\/abstract\/long-term-evolution-of-advanced-parkinsons-disease-burden-subgroup-analysis-from-the-24-month-international-prospect-observational-study\/. Accessed 27 May\u00a02025."},{"issue":"1","key":"856_CR8","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12883-019-1276-8","volume":"19","author":"A Fasano","year":"2019","unstructured":"Fasano A, Fung VSC, Lopiano L, et al. Characterizing advanced Parkinson\u2019s disease: OBSERVE-PD observational study results of 2615 patients. BMC Neurol. 2019;19(1):50.","journal-title":"BMC Neurol"},{"issue":"1","key":"856_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.18773\/austprescr.2025.003","volume":"48","author":"N Mouchaileh","year":"2025","unstructured":"Mouchaileh N, Cameron J. Device-assisted therapies for Parkinson disease. Aust Prescr. 2025;48(1):10\u20137.","journal-title":"Aust Prescr"},{"key":"856_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci9090239","author":"B Palakurthi","year":"2019","unstructured":"Palakurthi B, Burugupally SP. Postural instability in Parkinson\u2019s disease: a review. Brain Sci. 2019. https:\/\/doi.org\/10.3390\/brainsci9090239.","journal-title":"Brain Sci"},{"issue":"Suppl","key":"856_CR11","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/j.parkreldis.2007.06.005","volume":"13","author":"D Nyholm","year":"2007","unstructured":"Nyholm D. The rationale for continuous dopaminergic stimulation in advanced Parkinson\u2019s disease. Parkinsonism Relat Disord. 2007;13(Suppl):S13\u20137.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1\u20132","key":"856_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000455863","volume":"48","author":"K Horv\u00e1th","year":"2017","unstructured":"Horv\u00e1th K, Aschermann Z, Kov\u00e1cs M, et al. Changes in quality of life in Parkinson\u2019s disease: how large must they be to be relevant? Neuroepidemiology. 2017;48(1\u20132):1\u20138.","journal-title":"Neuroepidemiology"},{"key":"856_CR13","volume":"2015","author":"K Horv\u00e1th","year":"2015","unstructured":"Horv\u00e1th K, Aschermann Z, \u00c1cs P, et al. Minimal clinically important difference on Parkinson\u2019s disease sleep scale 2nd version. Parkinsons Dis. 2015;2015:970534.","journal-title":"Parkinsons Dis"},{"issue":"5","key":"856_CR14","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/mds.26960","volume":"32","author":"K Horv\u00e1th","year":"2017","unstructured":"Horv\u00e1th K, Aschermann Z, Kov\u00e1cs M, et al. Minimal clinically important differences for the experiences of daily living parts of movement disorder society-sponsored unified Parkinson\u2019s disease rating scale. Mov Disord. 2017;32(5):789\u201393.","journal-title":"Mov Disord"},{"key":"856_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2022.100181","volume":"8","author":"R Pahwa","year":"2023","unstructured":"Pahwa R, Aldred J, Merola A, et al. Long-term results of carbidopa\/levodopa enteral suspension across the day in advanced Parkinson\u2019s disease: post-hoc analyses from a large 54-week trial. Clin Parkinsonism Relat Disord. 2023;8:100181.","journal-title":"Clin Parkinsonism Relat Disord"},{"issue":"3","key":"856_CR16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3233\/JPD-225064","volume":"13","author":"A Alonso-Canovas","year":"2023","unstructured":"Alonso-Canovas A, Voeten J, Gifford L, Thomas O, Lees AJ, Bloem BR. The early treatment phase in Parkinson\u2019s disease: not a honeymoon for all, not a honeymoon at all? J Parkinsons Dis. 2023;13(3):323\u20138.","journal-title":"J Parkinsons Dis"},{"key":"856_CR17","first-page":"159","volume":"32","author":"A Antonini","year":"2025","unstructured":"Antonini A, Bergmans B, Gandor F, et al. EPO-271 Predictors of improvement in activities of daily living and QoL in patients treated with foslevodopa\/foscarbidopa. Eur J Neurol. 2025;32:159\u201360.","journal-title":"Eur J Neurol"},{"key":"856_CR18","volume":"6","author":"G Fern\u00e1ndez-Pajar\u00edn","year":"2022","unstructured":"Fern\u00e1ndez-Pajar\u00edn G, Sesar \u00c1, Jim\u00e9nez Mart\u00edn I, Ares B, Castro A. Continuous subcutaneous apomorphine infusion in the early phase of advanced Parkinson\u2019s disease: a prospective study of 22 patients. Clin Park Relat Disord. 2022;6:100129.","journal-title":"Clin Park Relat Disord"},{"issue":"7","key":"856_CR19","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1205158","volume":"368","author":"WM Schuepbach","year":"2013","unstructured":"Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson\u2019s disease with early motor complications. N Engl J Med. 2013;368(7):610\u201322.","journal-title":"N Engl J Med"},{"issue":"3","key":"856_CR20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2217\/nmt-2017-0046","volume":"8","author":"A Antonini","year":"2018","unstructured":"Antonini A, Robieson WZ, Bergmann L, Yegin A, Poewe W. Age\/disease duration influence on activities of daily living and quality of life after levodopa-carbidopa intestinal gel in Parkinson\u2019s disease. Neurodegener Dis Manag. 2018;8(3):161\u201370.","journal-title":"Neurodegener Dis Manag"},{"issue":"9","key":"856_CR21","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1080\/03007995.2021.1953971","volume":"37","author":"SS Jick","year":"2021","unstructured":"Jick SS, Oleske DM, Persson R, Zamudio J, Facheris MF. Epidemiology of skin event rates among users of pumps for the subcutaneous administration of drugs for chronic conditions. Curr Med Res Opin. 2021;37(9):1563\u201371.","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"856_CR22","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","volume":"17","author":"R Katzenschlager","year":"2018","unstructured":"Katzenschlager R, Poewe W, Rascol O, et al. Apomorphine subcutaneous infusion in patients with Parkinson\u2019s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2018;17(9):749\u201359.","journal-title":"Lancet Neurol"},{"key":"856_CR23","unstructured":"Odin P, Kimber T, Bergmans B, et al. Integrated analysis of phase\u00a03 trials of foslevodopa\/foscarbidopa demonstrated that majority of reported infusion site AEs including infections were non serious, mild to moderate in severity and did not result in treatment discontinuation [abstract]. Mov Disord 2023;38(suppl 1)."},{"key":"856_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2024.100239","volume":"10","author":"VSC Fung","year":"2024","unstructured":"Fung VSC, Aldred J, Arroyo MP, et al. Continuous subcutaneous foslevodopa\/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson\u2019s disease: considerations for initiation and maintenance. Clin Parkinsonism Relat Disord. 2024;10:100239.","journal-title":"Clin Parkinsonism Relat Disord"},{"key":"856_CR25","first-page":"244","volume":"32","author":"K Dashtipour","year":"2025","unstructured":"Dashtipour K, Pahwa R, Bergmans B, et al. EPO-425 Cluster analysis of patient characteristics associated with up to 100% \u201coff\u201d time improvement from two phase\u00a03 trials. Eur J Neurol. 2025;32:244\u20135.","journal-title":"Eur J Neurol"},{"key":"856_CR26","first-page":"53","volume":"2","author":"N Klepac","year":"2013","unstructured":"Klepac N, Habek M, Adamec I, et al. An update on the management of young-onset Parkinson\u2019s disease. Degener Neurol Neuromuscul Dis. 2013;2:53\u201362.","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"856_CR27","unstructured":"Real-world study of ABBV-951 subcutaneous infusion to assess change in disease activity in adult participants with Parkinson\u2019s disease (ROSSINI). ClinicalTrials.gov identifier: NCT06107426. https:\/\/clinicaltrials.gov\/study\/NCT06107426. Accessed 27 May\u00a02025."},{"key":"856_CR28","unstructured":"Study to assess real life effectiveness of foslevodopa\/foscarbidopa in adult german participants at initial stages of advanced Parkinson\u2019s disease (EARLY-FOS). ClinicalTrials.gov identifier: NCT06916507. https:\/\/clinicaltrials.gov\/study\/NCT06916507. Accessed 27 May\u00a02025."},{"key":"856_CR29","unstructured":"Real-world study of foslevodopa\/foscarbidopa to assess quality of life outcomes in adult participants with advanced Parkinson disease (FREELIFE). ClinicalTrials.gov identifier: NCT06965374. https:\/\/clinicaltrials.gov\/study\/NCT06965374. Accessed 27 May\u00a02025."},{"key":"856_CR30","unstructured":"Study to assess effectiveness and adverse events of foscarbidopa\/foslevodopa in adult participants with advanced Parkinson disease in real life setting (ENVOL). ClinicalTrials.gov identifier: NCT06639620. https:\/\/clinicaltrials.gov\/study\/NCT06639620. Accessed 27 May\u00a02025."},{"key":"856_CR31","unstructured":"Study on practical experiences of treatment with foslevodopa\/foscarbidopa in advanced Parkinson\u2019s disease (ORCHESTRA). ClinicalTrials.gov identifier: NCT06937034. https:\/\/clinicaltrials.gov\/study\/NCT06937034. Accessed 27 May\u00a02025."}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00856-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00856-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00856-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T13:51:38Z","timestamp":1768398698000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00856-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["856"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00856-1","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Angelo Antonini has received compensation for consultancy and speaker-related activities from AbbVie, Bayer, Bial, Britannia, Ever Pharma, Ferrer Teva, Roche, Stada, Theravance Biopharma, and Zambon and receives research support from Horizon2020 Grant 101016902, Ministry of University and Research (MUR), Ministry of Health, European Union\u2014NextGenerationEU\u2014NRRP M6C2\u2014Investment: 2.1 \u201cEnhancement and strengthening of biomedical research within the NSH.\u201d Bruno Bergmans has received investigator-initiated grants from AbbVie. He has a clinical practice at AZ St-Jan Brugge in Brugge, Belgium, and is an academic consultant at Ghent University Hospital in Ghent, Belgium. He is the principal investigator for multiple clinical trials in Brugge, Belgium. He has received investigator-initiated grants from Merz Pharma GmbH; has served as a speaker for EG, Merz GmbH, Teva, and Zambon; and has served as an advisory board member for AbbVie, Abbott, Boston Scientific, EG, Ipsen, Merz GmbH, Orion Pharma, Teva, and UCB. His institution has received grants from AbbVie, Abbott, Boston Scientific, EG (for the organization of a deep-brain stimulation symposium sponsored by the International Parkinson and Movement Disorders Society), Elekta, GSK, Ipsen, Medtronic, Merck, Merz GmbH, Orion Pharma, Schwabe, and Teva. Drew S Kern has served as an advisor for the Colorado Clinical and Translational Sciences Institute (CCTSI) Data Safety Monitoring Board; has received honoraria for advisement\/consulting from AbbVie, Abbott, Alpha Omega Engineering, Boston Scientific, and Medtronic; and has received grants from Boston Scientific and Medtronic. Florin Gandor has served as an advisory board member for AbbVie and has received honoraria from AbbVie, Bial Pharma, Merz, and Stada. Noriko Nishikawa has received speaker honoraria from AbbVie GK, Eisai, Ono, and Takeda and has served as an advisor for AbbVie. David G Standaert is a member of the faculty of the University of Alabama at Birmingham and is supported by endowment and University funds. He is an investigator in studies funded by the AbbVie, the American Parkinson Disease Association, the Michael J. Fox Foundation for Parkinson Research, The National Parkinson Foundation, the Alabama Department of Commerce, the Alabama Innovation Fund, Genentech, the Department of Defense, and NIH grants P50NS108675 and R25NS079188. He has a clinical practice and is compensated for his services through the University of Alabama Health Services Foundation. He serves as Deputy Editor for the journal\n                      Movement Disorders\n                      and is compensated for this role by the International Parkinson and Movement Disorders Society. In addition, since January 1, 2022, he has served as a consultant for or received honoraria from AbbVie, Alnylam, Appello, Biohaven, BlueRock, Coave, Curium, F. Hoffman-La Roche, Lilly, Sanofi-Aventis, and Theravance. He has also received book royalties from McGraw-Hill Publishers. Bjoern Fritz, Resmi Gupta, Toshiki Nozaki, Megha B Shah, and Lars Bergmann are full-time employees of AbbVie, and may hold AbbVie stock and\/or stock options. Thomas Kimber has received honoraria from AbbVie and Seqiris.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol, recruitment materials, and informed consent forms were approved by independent ethics committees or institutional review boards at each study site before enrollment. The study was conducted in accordance with the International Council for Harmonisation guidelines, the Declaration of Helsinki, and all applicable regional regulations. Patients and their care partners (if applicable) provided written informed consent before screening.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}